Royal London UK Dividend Growth A

The investment objective of the Scheme is to maximise capital growth.

  • 313.50p
    Price (Inc)

    These are the shares in the fund that pay out an income to clients. The income is made up of the total dividends – the money a company can pay out to its investors – from the companies in the fund.

  • -
    Price (Acc)

    These are the shares in the fund that don’t pay out an income to clients. Any dividends – the money a company can pay out to its investors – are reinvested into companies in the fund. Despite no income, the shares should be worth more over time. Good incentive, eh?

  • 4.00% 0.00%

    Initial charge

    Some funds charge you when you first invest, which is aptly known as the initial charge. They’re usually between 3-5% but at Bestinvest, we usually don’t charge you a penny!

  • 1.25%
    Annual management charge

    This is how much the fund management company charges to run the fund. It’s like paying a babysitter, dog sitter or house sitter (that makes well-informed, heavily researched changes to improve your baby/dog/house when needed).

  • 1.30%
    Ongoing charges

    This stands for Ongoing Charges Figure. It’s the cost of running a fund and includes admin fees, manager fees, administration costs, etc.

  • 3.70%
    Yield

    How much the fund is currently paying out in income to investors. It’s NOT to be confused with the overall growth of a fund – a very different thing indeed. It’s also NOT a guarantee of future pay-outs, just a snapshot. This is more what it’s not than what it is…

Prices as at 25 September 2020

Fund summary

Sector UK All Companies
Structure OEIC
Launched June, 1981
Size £797m
Yield 3.70%
Charging basis Income
Dividends paid Acc units only

Charges

Standard initial charge 4.00%
Initial charge via Bestinvest 0.00%
Additional bid/offer spread 0.00%
Annual management charge 1.25%
Ongoing charges figure 1.30%

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Investment process

The investment objective of the Scheme is to maximise capital growth.

Manager research

Average monthly relative returns

  • 15/16 0.00%
  • 16/17 0.10%
  • 17/18 0.43%
  • 18/19 -0.22%
  • 19/20 0.67%

Bestinvest MRI

  • 3 years 0.29%
  • 5 years 0.00%
  • Career 0.03%
  • 3 years 97.50%
  • 5 years 0.00%
  • Career 76.10%

Performance figures are based on the average of monthly percentage returns relative to the benchmark index.

Richard Marwood

Marwood joined AXA Sun Life Investment Management in 1996 as a Portfolio Manager in UK Equities and has occupied a similar position for AXA IM UK since 2000. He graduated with a First Class Honours Degree in Mechanical Engineering from the University of Sheffield and a Postgraduate Degree in Aerodynamics from Lincoln College, University of Oxford.

Track record

Richard Marwood has 7.3 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been +0.03%. During the worst period of relative performance (from June 2003 - November 2008) there was a decline of 12% relative to the index. The worst absolute loss has been 37%. Statistically, we estimate the probability that this fund manager is adding value, rather than being lucky, is 76%.

Periods of worst performance

Absolute -37.00% (November 2004 - February 2009)
Relative -12.00% (June 2003 - November 2008)

About the MRI

Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Top 10 holdings

Data accurate as at 31 July 2020

4.9277% Astrazeneca Plc
3.2704% B & M European Value Retail Sa
3.262% Royal Dutch Shell Plc
3.175% Hikma Pharmaceuticals Plc
3.1106% Relx Nv
3.0984% Fevertree Drinks Plc
2.9626% Rio Tinto
2.8935% Ashtead Group
2.8225% Bunzl
2.7498% Glaxosmithkline
Source: Trustnet

Sector breakdown

Industrials 17.00%
Financials 17.00%
Health Care 15.00%
Consumer Services 14.00%
Consumer Goods 14.00%
Basic Materials 9.00%
Oil & Gas 6.00%
Utilities 4.00%
Technology 4.00%

Key Investor Information

Download